miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme

被引:98
|
作者
Yin, D. [1 ,2 ,3 ]
Ogawa, S. [4 ]
Kawamata, N. [3 ]
Leiter, A. [3 ]
Ham, M. [3 ]
Li, D. [5 ]
Doans, N. B.
Said, J. W. [6 ]
Black, K. L. [7 ]
Koeffler, H. Phillip [3 ,8 ,9 ]
机构
[1] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Med Res Ctr, Key Lab Malignant Tumor Gene Regulat, Guangzhou 510275, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Med Res Ctr, Target Therapy Guangdong Higher Educ Inst, Guangzhou 510275, Guangdong, Peoples R China
[3] Univ Calif Los Angeles, Sch Med, Div Hematol Oncol, Cedars Sinai Med Ctr, Los Angeles, CA 90024 USA
[4] Univ Tokyo, Sch Med, Tokyo 113, Japan
[5] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA
[6] Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90024 USA
[7] Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Maxine Dunitz Neurosurg Inst, Los Angeles, CA USA
[8] Natl Univ Hlth Syst, Natl Univ Canc Inst Singapore, Dept Hematol Oncol, Singapore, Singapore
[9] Natl Univ Singapore, Canc Sci Inst, Singapore 117548, Singapore
基金
美国国家卫生研究院;
关键词
glioblastoma multiforme; genomic profiling; miR-34a; EGFR; YY-1; GROWTH-FACTOR RECEPTOR; PROSTATE-CANCER; DOWN-REGULATION; EXPRESSION PROFILES; GENE-EXPRESSION; C-MET; APOPTOSIS; IDENTIFICATION; NEUROBLASTOMA; PATHWAY;
D O I
10.1038/onc.2012.132
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chromosome 1p36.23 is frequently deleted in glioblastoma multiforme (GBM). miR-34a localizes in this region. Our experiments found that miR-34a was often deleted and epidermal growth factor receptor (EGFR) was frequently amplified in genomic DNA of 55 GBMs using single-nucleotide polymorphism DNA microarray. Notably, we found that the mean survival time was significantly shortened for patients whose GBMs had both EGFR amplification and miR-34a deletion. Expression of miR-34a was significantly lower in GBM samples compared with normal brain tissue. Forced expression of miR-34a in GBM cells decreased their ability to migrate and profoundly decreased their levels of cyclin-A1, -B1, -D1, and -D3, as well as cyclin-dependent kinase and increased expression of cyclin kinase inhibitor proteins (p21, p27). Also, human GBM cells (U251) stable overexpressing mir-34a formed smaller tumors when growing as xenografts in immunodeficient mice compared with wild-type U251 GBM cells. Furthermore, the protein expression of EGFR decreased in the cells with forced overexpression of miR-34a. Additional studies showed that mir-34a targeted Yin Yang-1 (YY1) and YY1 is a transcription factor that can stimulate the expression of EGFR. Thus, our data suggest that miR-34a acts as a tumor suppressor by inhibiting growth of GBM cells in vitro and in vivo associated with moderating the expression of cell-cycle proteins and EGFR. Moreover, we discovered for the first time that both deletion of miR-34a and amplification of EGFR were associated with significantly decreased overall survival of GBM patients. Oncogene (2013) 32, 1155-1163; doi:10.1038/onc.2012.132; published online 14 May 2012
引用
收藏
页码:1155 / 1163
页数:9
相关论文
共 50 条
  • [31] DGKZ-TARGETED REGULATION OF MIR-34A IN THE PROLIFERATION AND TUMORIGENICITY OF HUMAN GLIOBLASTOMA
    Gu, Wangxian
    Wan, Guoqing
    Zheng, Yanjun
    Yang, Xintong
    Zhang, Peng
    Lu, Changlian
    Gu, Xuefeng
    NEURO-ONCOLOGY, 2020, 22 : 13 - 13
  • [32] Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma
    Khan, Muhammad Babar
    Ruggieri, Rosamaria
    Jamil, Eesha
    Tran, Nhan L.
    Gonzalez, Camila
    Mugridge, Nancy
    Gao, Steven
    MacDiarmid, Jennifer
    Brahmbhatt, Himanshu
    Sarkaria, Jann N.
    Boockvar, John
    Symons, Marc
    MOLECULAR MEDICINE, 2021, 27 (01)
  • [33] Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma
    Muhammad Babar Khan
    Rosamaria Ruggieri
    Eesha Jamil
    Nhan L. Tran
    Camila Gonzalez
    Nancy Mugridge
    Steven Gao
    Jennifer MacDiarmid
    Himanshu Brahmbhatt
    Jann N. Sarkaria
    John Boockvar
    Marc Symons
    Molecular Medicine, 2021, 27
  • [34] Association of miR-34a Expression with Quality of Life of Glioblastoma Patients: A Prospective Study
    Vaitkiene, Paulina
    Pranckeviciene, Aiste
    Stakaitis, Rytis
    Steponaitis, Giedrius
    Tamasauskas, Arimantas
    Bunevicius, Adomas
    CANCERS, 2019, 11 (03)
  • [35] NANOCELL-MEDIATED DELIVERY OF MIR-34A COUNTERACTS TEMOZOLOMIDE RESISTANCE IN GLIOBLASTOMA
    Khan, Muhammad Babar
    Ruggieri, Rosamaria
    Nhan Tran
    Sarkaria, Jann
    MacDiarmid, Jennifer
    Brahmbhatt, Himanshu
    Boockvar, John
    Symons, Marc
    NEURO-ONCOLOGY, 2019, 21 : 66 - 67
  • [36] C-Myc negatively controls the tumor suppressor PTEN by upregulating miR-26a in glioblastoma multiforme cells
    Guo, Pin
    Nie, Quanmin
    Lan, Jin
    Ge, Jianwei
    Qiu, Yongming
    Mao, Qing
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2013, 441 (01) : 186 - 190
  • [37] Identification of miPEP133 as a novel tumor-suppressor microprotein encoded by miR-34a pri-miRNA
    Kang, Min
    Tang, Bo
    Li, Jixi
    Zhou, Ziyan
    Liu, Kang
    Wang, Rensheng
    Jiang, Ziyan
    Bi, Fangfang
    Patrick, David
    Kim, Dongin
    Mitra, Anirban K.
    Yang-Hartwich, Yang
    MOLECULAR CANCER, 2020, 19 (01)
  • [38] Enhancer of zeste homolog 2 couples with HOTAIR to inhibit tumor suppressor miR-34a in human pancreatic ductal adenocarcinoma
    Li, Samson
    Chen, Yangchao
    CANCER RESEARCH, 2015, 75
  • [39] Effect of Tumor Suppressor MiR-34a Loaded on ZSM-5 Nanozeolite in Hepatocellular Carcinoma: In Vitro and In Vivo Approach
    Salah, Zeinab
    Abd El Azeem, Eman M.
    Youssef, Hanan F.
    Gamal-Eldeen, Amira M.
    Farrag, Abdel Razik
    El-Meliegy, Emad
    Soliman, Bangly
    Elhefnawi, Mahmoud
    CURRENT GENE THERAPY, 2019, 19 (05) : 342 - 354
  • [40] EGFR LIGAND SHIFTS THE ROLE OF EGFR FROM ONCOGENE TO TUMOR SUPPRESSOR IN EGFR AMPLIFIED GLIOBLASTOMA
    Guo, Gao
    Gong, Ke
    Beckley, Nicole
    Zhang, Yue
    Yang, Xiaoyao
    Nayab, Arifa
    Habib, Amyn
    NEURO-ONCOLOGY, 2022, 24 : 38 - 39